MONTREAL, Feb. 28, 2013 /CNW Telbec/ - BIOQuébec is pleased to announce the appointment of Dr. Martin Godbout as
chairman of the Board, replacing Mr. Gilles R. Gagnon, who held this
position during the last 2 years. Mr. Godbout's appointment comes into
"Since its creation, BIOQuébec has played a key role as spokesperson of the biotechnology
industry. It is with humility that I accept to collaborate, with all
members of the Board, towards the development of strategies that will
further the industry and promote the life sciences sector not only in
Québec but abroad", stated Dr. Godbout.
As director on BIOQuébec's Board for the last 2 years, Dr. Godbout also sits on several other
Boards of biotechnology companies, foundations and Canadian scientific
organizations. He is president of the MethylGene inc. and Génome Québec Boards and acts as director on the Boards of the
following organizations: Acasti Pharma Inc., AmorChem Inc., AngioChem Inc., AsmaCure Inc., BioContact, the Fonds de recherche du Québec - santé (FQRS), Montréal In Vivo and the Fondation de l'Ataxie de Charlevoix.
Dr. Godbout founded Génome Canada, and was its president and CEO for many years. Throughout his career,
he sat on the Science and Technology Council of Québec and was a member of the Natural Sciences and Engineering Research Council of Canada. He also developed BioContact Québec, an annual symposium on biopharmaceutical partnerships. He held the
position of senior vice-president of BioCapital, a major Canadian venture capital firm. Prior to this, he was CEO of Société Innovatech Québec, a technology investment fund. Dr. Godbout is an Officer of the Order of Canada and has received numerous awards in Canada and abroad.
BIOQuébec's Board of Directors would like to thank Mr. Gagnon for his contribution
to the association and wishes him much luck in his future projects.
BIOQuébec is a biotechnology and life science industry association representing
nearly 100 member companies and R&D centres in Québec. The association
works to create a positive business environment which fosters the
growth of the life science industry, including access to capital and
access to development and marketing partners, workforce development, a
regulatory and competitive tax environment and the promotion of its
members among various publics both in Québec and on an international
Board of Directors 2012-2013
Dr. Martin Godbout
President of the Board
Hodran Consultants Inc.
Prevtec microbia inc.
John-Michel T. Huss
Corealis Pharma Inc.
Teralys Capital Inc.
Davies Ward Phillips & Vineberg, s.r.l.
BIO-K + International Inc.
Oncozyme Pharma Inc.
Chief Scientific Officer
Novartis Pharma Canada Inc.
Dr. Pavel Hamet
Vice-President, Public Affairs and Reimbursement
For further information: